Search Results - "Kay, NE"

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy by Ioannou, Nikolaos, Hagner, Patrick R., Stokes, Matt, Gandhi, Anita K., Apollonio, Benedetta, Fanous, Mariam, Papazoglou, Despoina, Sutton, Lesley-Ann, Rosenquist, Richard, Amini, Rose-Marie, Chiu, Hsiling, Lopez-Girona, Antonia, Janardhanan, Preethi, Awan, Farrukh T., Jones, Jeffrey, Kay, Neil E., Shanafelt, Tait D., Tallman, Martin S., Stamatopoulos, Kostas, Patten, Piers E.M., Vardi, Anna, Ramsay, Alan G.

“…Cancer treatment has been transformed by checkpoint blockade therapies, with the highest anti-tumor activity of anti-programmed death 1 (PD-1) antibody therapy…”
Get full text

IκBε deficiency accelerates disease development in chronic lymphocytic leukemia by Bordini, Jessica, Lenzi, Chiara, Frenquelli, Michela, Morabito, Alessia, Pseftogas, Athanasios, Belloni, Daniela, Mansouri, Larry, Tsiolas, George, Perotta, Eleonora, Ranghetti, Pamela, Gandini, Francesca, Genova, Francesca, Hägerstrand, Daniel, Gavriilidis, Georgios, Keisaris, Sofoklis, Pechlivanis, Nikolaos, Davi, Frederic, Kay, Neil E., Langerak, Anton W., Pospisilova, Sarka, Scarfò, Lydia, Makris, Antonios, Psomopoulos, Fotis E., Stamatopoulos, Kostas, Rosenquist, Richard, Campanella, Alessandro, Ghia, Paolo

“…The NFKBIE gene, which encodes the NF-κB inhibitor IκBε, is mutated in 3–7% of patients with chronic lymphocytic leukemia (CLL). The most recurrent alteration…”
Get full text

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations : Analysis of the Eastern cooperative oncology group phase III trial by LIU, P, LEONG, T, QUAM, L, BILLADEAU, D, KAY, N. E, GREIPP, P, KYLE, R. A, OKEN, M. M, VAN NESS, B

“…Mutations of members of the ras family are among the most common oncogene mutations found in multiple myeloma (MM). We have examined the mutational status of…”
Get full text

The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia by Hägerstrand, Daniel, Oder, Blaž, Cortese, Diego, Qu, Ying, Binzer-Panchal, Amrei, Österholm, Cecilia, Del Peso Santos, Teresa, Rabbani, Leily, Asl, Hassan Foroughi, Skaftason, Aron, Ljungström, Viktor, Lundholm, August, Koutroumani, Maria, Haider, Zahra, Jylhä, Cecilia, Mollstedt, John, Mansouri, Larry, Plevova, Karla, Agathangelidis, Andreas, Scarfò, Lydia, Armand, Marine, Muggen, Alice F., Kay, Neil E., Shanafelt, Tait, Rossi, Davide, Orre, Lukas M., Pospisilova, Sarka, Barylyuk, Konstantin, Davi, Frederic, Vesterlund, Mattias, Langerak, Anton W., Lehtiö, Janne, Ghia, Paolo, Stamatopoulos, Kostas, Sutton, Lesley-Ann, Rosenquist, Richard

“…SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their…”
Get full text

ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia by Rassenti, Laura Z, Huynh, Lang, Toy, Tracy L, Chen, Liguang, Keating, Michael J, Gribben, John G, Neuberg, Donna S, Flinn, Ian W, Rai, Kanti R, Byrd, John C, Kay, Neil E, Greaves, Andrew, Weiss, Arthur, Kipps, Thomas J

“…Variations in the clinical course of chronic lymphocytic leukemia (CLL) make decisions about treatment difficult. In more than 300 patients with the disease,…”
Get full text

Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL by Shanafelt, Tait D., Geyer, Susan M., Kay, Neil E.

“…Heterogeneity in the clinical behavior of patients with chronic lymphocytic leukemia (CLL) makes it difficult for physicians to accurately identify which…”
Get full text

Neuropeptides: conductors of the immune orchestra by Morley, J E, Kay, N E, Solomon, G F, Plotnikoff, N P

“…There is increasing evidence for a bidirectional communications system between the immune system and the brain. Many of the substances involved in this…”
Get more information

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia by Lee, Yean K., Bone, Nancy D., Strege, Ann K., Shanafelt, Tait D., Jelinek, Diane F., Kay, Neil E.

“…We recently reported that chronic lymphocytic leukemia (CLL) cells synthesize and release vascular endothelial growth factor (VEGF) under normoxic and hypoxic…”
Get full text

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia by Kaufman, Matthew, Yan, Xiao-Jie, Li, Wentian, Ghia, Emanuela M, Langerak, Anton W, Rassenti, Laura Z, Belessi, Chrysoula, Kay, Neil E, Davi, Frederic, Byrd, John C, Pospisilova, Sarka, Brown, Jennifer R, Catherwood, Mark, Davis, Zadie, Oscier, David, Montillo, Marco, Trentin, Livio, Rosenquist, Richard, Ghia, Paolo, Barrientos, Jacqueline C, Kolitz, Jonathan E, Allen, Steven L, Rai, Kanti R, Stamatopoulos, Kostas, Kipps, Thomas J, Neuberg, Donna, Chiorazzi, Nicholas

“…Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins…”
Get full text

Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival by Novak, Anne J., Bram, Richard J., Kay, Neil E., Jelinek, Diane F.

“…B-cell chronic lymphocytic leukemia (B-CLL) is defined by the accumulation of CD5+ B cells in the periphery and bone marrow. This disease is not characterized…”
Get full text

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients by Fonseca, Rafael, Blood, Emily A., Oken, Martin M., Kyle, Robert A., Dewald, Gordon W., Bailey, Richard J., Van Wier, Scott A., Henderson, Kimberly J., Hoyer, James D., Harrington, David, Kay, Neil E., Van Ness, Brian, Greipp, Philip R.

“…The t(11;14)(q13;q32) results in up-regulation of cyclin D1 and is the most common translocation detected in multiple myeloma, where it is also associated with…”
Get full text

Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse by Braggio, E, Kay, N E, VanWier, S, Tschumper, R C, Smoley, S, Eckel-Passow, J E, Sassoon, T, Barrett, M, Van Dyke, D L, Byrd, J C, Jelinek, D F, Shanafelt, T D, Fonseca, R

Get full text

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance by LEE, Y. K, SHANAFELT, T. D, BONE, N. D, STREGE, A. K, JELINEK, D. F, KAY, N. E

“…We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active…”
Get full text

The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia by Hallek, Michael, Kay, Neil E, Osterborg, Anders, Chanan-Khan, Asher A, Mahler, Michelle, Salman, Mariya, Wan, Ying, Sun, Steven, Zhuang, Sen Hong, Howes, Angela

“…Ibrutinib is an orally administered, covalent inhibitor of Bruton's tyrosine kinase with activity in B-cell malignancies based on Phase I/II studies. We…”
Get full text

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia by Dewald, Gordon W., Brockman, Stephanie R., Paternoster, Sarah F., Bone, Nancy D., O'Fallon, Judith R., Allmer, Cristine, James, Charles D., Jelinek, Diane F., Tschumper, Renee C., Hanson, Curtis A., Pruthi, Rajiv K., Witzig, Thomas E., Call, Timothy G., Kay, Neil E.

“…Fluorescence in situ hybridization (FISH) was used to detect 6q–, 11q–, +12, 13q–, 17p– and translocations involving 14q32 in interphase nuclei from blood…”
Get full text

ROS: double-edged sword for leukemic cells by Kay, Neil E.

“…Comment on Chandra et al, page 2501 There is increasing evidence that chemotherapeutic drugs can work via acceleration of reactive oxygen species in human…”
Get full text

The Clinical and Biologic Importance of Neovascularization and Angiogenic Signaling Pathways in Chronic Lymphocytic Leukemia by Shanafelt, Tait D., Kay, Neil E.

“…Angiogenesis has been found to be an important regulator in the growth and metastasis of solid tumors. More recent studies have also demonstrated the…”
Get full text

Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: An Eastern Cooperative Oncology Group study by FONSECA, Rafael, HARRINGTON, David, VAN NESS, Brian, GREIPP, Philip R, OKEN, Martin M, DEWALD, Gordon W, BAILEY, Richard J, VAN WIER, Scott A, HENDERSON, Kimberly J, BLOOD, Emily A, RAJKUMAR, S. Vincent, KAY, Neil E

“…Chromosome 13 abnormalities (Delta13) have been associated with an unfavorable prognosis in patients with multiple myeloma (MM). The significance of this has…”
Get full text

Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia by KINI, A. R, KAY, N. E, PETERSON, L. C

“…Recent studies have shown that angiogenesis may be involved in the pathogenesis of hematopoietic malignancies, apart from its well-characterized role in the…”
Get full text

Complete response in multiple myeloma : Clinical trial E9486, an eastern cooperative oncology group study not involving stem cell transplantation by KYLE, Robert A, LEONG, Traci, SHULI LI, OKEN, Martin M, KAY, Neil E, VAN NESS, Brian, GREIPP, Philip R

“…The importance of obtaining a complete response (CR) in multiple myeloma (MM) treated with chemotherapy is unclear. The Eastern Cooperative Oncology Group…”
Get full text